For the quarter ending 2025-09-30, ANAB made $76,320K in revenue. $15,166K in net income. Net profit margin of 19.87%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Collaboration revenue | 76,320 | 22,263 | 27,771 | 25,146 |
| Research and development | 31,407 | 37,824 | 41,180 | - |
| General and administrative | 10,209 | 10,609 | 14,130 | 11,266 |
| Research and development | - | - | - | 40,960 |
| Total operating expenses | 41,616 | 48,433 | 55,310 | 51,082 |
| Income (loss) from operations | 34,704 | -26,170 | -27,539 | -25,935 |
| Interest income | 2,924 | 3,654 | 4,413 | 4,924 |
| Non-cash interest expense for the sale of future royalties | 22,515 | 19,606 | 18,061 | 11,861 |
| Other (expense) income, net | 0 | 3,531 | 1,902 | 6 |
| Total other expense, net | -19,591 | -12,421 | -11,746 | -6,927 |
| Income (loss) before income taxes | 15,113 | -38,591 | -39,285 | -32,863 |
| Provision for income taxes | 0 | 39 | 44 | -2 |
| Net income (loss) | 15,113 | -38,630 | -39,329 | -32,860 |
| Unrealized gain (loss) on available for sale securities | 53 | -167 | -144 | -140 |
| Comprehensive income (loss) | 15,166 | -38,797 | -39,473 | -33,000 |
| Basic (in dollars per share) | 0.54 | -1.34 | -1.28 | -1.135 |
| Basic (in shares) | 27,833,000 | 28,810,000 | 30,644,000 | -13,933,500 |
| Diluted (in dollars per share) | 0.52 | -1.34 | -1.28 | -1.135 |
| Diluted (in shares) | 29,018,000 | 28,810,000 | 30,644,000 | -13,933,500 |
ANAPTYSBIO, INC (ANAB)
ANAPTYSBIO, INC (ANAB)